Panacea Biotec Ltd

Panacea Biotec Ltd

$PANACEABIOPharmaceuticalsNSEBSE

Panacea Biotec Ltd (PANACEABIO) last traded at ₹406, a market capitalisation of ₹2,487 crore. Over the past 52 weeks the stock has ranged between ₹292 and ₹648. Panacea Biotec Ltd last reported results for the quarter ended Jun 2026, with sales of ₹200 crore and net profit of ₹2.2 crore. Panacea Biotec Ltd’s annual general meeting is scheduled for 29 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.

Panacea Biotec Ltd share price and key metrics

Current price
₹406
Market cap
₹2,487 cr
Book value
₹136
ROE
-2.36%
ROCE
-2.44%
Dividend yield
0.00%
52w high / low
648/292

Metrics as of 25 Aug 2026. Not real time.

Panacea Biotec Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹200 cr, up 19.7% from ₹167 cr a year earlier. Net profit was ₹2.2 cr, down 44.4% year on year.

Panacea Biotec Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales147163133167141165167200
Expenses140156159168159153164194
Operating profit77.96-26.88-1.18-17.7911.742.575.67
OPM %4.75%4.87%-20.28%-0.71%-12.61%7.11%1.54%2.84%
Other income7.426.3936.316.999.15.055.266.98
Interest0.980.991.040.862.141.851.21.18
Depreciation8.688.988.428.398.348.457.887.9
Profit before tax4.764.38-0.046.56-19.176.49-1.253.57
Tax %1.05%-1.37%4,875.00%39.63%-26.92%40.06%-20.00%38.38%
Net profit4.714.44-1.993.96-14.013.89-12.2
EPS (₹)0.780.74-0.310.66-2.270.650.080.38

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Panacea Biotec Ltd annual results

Panacea Biotec Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales625661460559559640673
Operating profit77-13-98-20-25-52
OPM %12%-2.0%-21%-3.5%-4.4%-0.7%0.3%
Net profit-1481,078-34-2-9-7-9
EPS (₹)-24.09175.91-5.42-0.19-1.37-0.88-1.16

TTM is the trailing twelve months to the most recent quarter.

Panacea Biotec Ltd growth and returns

Compounded Sales Growth
10 Years
0%
5 Years
0%
3 Years
12%
TTM
10%
Compounded Profit Growth
10 Years
5%
5 Years
13%
3 Years
21%
TTM
43%
Stock Price CAGR
10 Years
15%
5 Years
6%
3 Years
43%
1 Year
1%
Return on Equity
10 Years
%
5 Years
-10%
3 Years
-3%
Last Year
-2%

Panacea Biotec Ltd shareholding pattern

Promoters held 72.48% at Jun 2026, broadly unchanged since Jun 2025. FIIs 2.31% and DIIs 2.25%.

Panacea Biotec Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters72.87%72.49%72.48%72.48%72.48%72.48%72.48%72.48%
FIIs0.37%0.38%1.16%0.79%1.06%1.36%1.60%2.31%
DIIs1.16%1.16%1.49%1.52%1.80%1.85%1.96%2.25%
Public25.60%25.96%24.86%25.20%24.65%24.31%23.96%22.96%
No. of shareholders39,98235,44633,59334,25633,59334,59732,62033,532

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

When is Panacea Biotec Ltd’s AGM?

Panacea Biotec Ltd’s annual general meeting is scheduled for 29 Sept 2026.

  • AGM42nd Annual General Meeting

See the full results calendar for every Indian company reporting in the next 30 days.

Panacea Biotec Ltd corporate filings

  • Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Panacea Biotec Limited has issued a public notice regarding its 42nd Annual General…

    Read the full analysis
  • Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatemedium impact
    Filing PDF

    Cruxal's analysis: Panacea Biotec Limited has released its unaudited standalone and consolidated financial…

    Read the full analysis
  • Board Meeting Outcome for Outcome Of Board Meeting Held On August 13, 2026Board Meetinghigh impact
    Filing PDF

    Cruxal's analysis: Panacea Biotec Limited has reported a return to profitability for the quarter ended June…

    Read the full analysis
  • Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Panacea Biotec has published a newspaper notice informing shareholders about the opening…

    Read the full analysis
  • Panacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Standalone and Consolidated ....Board Meetinglow impact
    Filing PDF

    Cruxal's analysis: Panacea Biotec Limited has formally notified the stock exchanges that its Board of…

    Read the full analysis
  • Details Of Shares Dematerialized During July 2026 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Panacea Biotec Ltd has submitted its routine compliance filing under Regulation 74(5) of…

    Read the full analysis
  • We are delighted to inform you that the Company has received Letter of Award for supply of bivalent Oral Polio Vaccine (bOPV) to UNICEF in 10 and 20 dose presentation worth ~US$8.205 million ....Company Updatemedium impact
    Filing PDF

    Cruxal's analysis: Panacea Biotec Limited has received a Letter of Award from UNICEF for the supply of…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Panacea Biotec Ltd

Cruxal reads every Panacea Biotec Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.